Low-Dose Alfentanil Inhibits Sufentanil-Induced Cough During Anesthesia Induction: A Prospective, Randomized, Double-Blind Study
DOI: https://doi.org/10.2147/dddt.s464823
IF: 4.3188
2024-05-18
Drug Design Development and Therapy
Abstract:Qiaomin Xu, 1 Xintong Zou, 2 Jimin Wu, 1 Gongchen Duan, 1 Haiyan Lan, 1 Liangrong Wang 2 1 Department of Anesthesiology, Lishui People's Hospital, Lishui, 323000, People's Republic of China; 2 Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China Correspondence: Liangrong Wang, The First Affiliated Hospital of Wenzhou Medical University, No. 2, Fuxue Road, Lucheng District, Wenzhou City, Zhejiang Province, 325000, People's Republic of China, Tel +86 13587884540, Email Background: Cough is one of the most common complications following intravenous administration of sufentanil during anesthesia induction. The study aimed to investigate the protective effect of alfentanil, afentanyl derivative with short onset time and short duration, in reducing sufentanil-induced cough. Patients and methods: Eighty patients that scheduled for thyroid surgery under general anesthesia were randomly divided into the alfentanil group and normal saline group, with 40 cases per group. Patients in the alfentanil group received intravenous administration of 2 μg/kg alfentanil prior to sufentanil injection during general anesthesia induction, while the same dose of normal saline was administered in the normal saline group. The outcomes measures included the incidence and severity of cough and common side effects of opioids following the administration of sufentanil during the induction of general anesthesia, intraoperative hemodynamics parameters and major adverse events during anesthesia recovery period. Results: The incidence of cough within one minute after the injection of sufentanil during anesthesia induction was 40% in the normal saline group, and the pretreatment of alfentanil significantly reduced the incidence of sufentanil-induced cough to 5% (p < 0.05). Correspondingly, the patients in the alfentanil group had decreased severity of sufentanil-induced cough compared with the normal saline group (p 0.05). Furthermore, there were no significant differences between the two groups in intraoperative hemodynamic parameters, extubation time, or the incidences of emergence agitation, respiratory depression, delayed recovery from anesthesia and postoperative nausea and vomiting during Postanesthesia Care Unit stay (p > 0.05). Conclusion: Pretreatment with low-dose alfentanil (2 μg/kg) effectively and safely reduced both the incidence and severity of sufentanil-induced cough during anesthesia induction. Clinical Trial Registration Number: Chinese Clinical Trial Registry (identifier: ChiCTR2300069286). Keywords: alfentanil, sufentanil, cough, anesthesia induction Sufentanil, a synthesized opioid agonist, has been widely used for the induction of general anesthesia in clinical practice due to its reliable analgesic efficacy, lack of histamine release and little effect on hemodynamics. Whereas, the use of intravenous sufentanil can be associated with a number of undesirable effects, such as nausea, vomiting, cough, chest tightness, dizziness and even respiratory depression, depending on the dose, injection speed and individual variation. Sufentanil-induced cough, with an incidence of up to 31.9%, 1 is usually transient and explosive, and in severe cases it can increase intracranial, intraocular and intraabdominal pressures, which may even cause a range of adverse effects in patients with high-risk comorbidities. 2 Several medicines, such as lidocaine, propofol, fentanyl, remifentanil, dezocine, dexmedetomidine, tramadol or magnesium sulfate, have been shown to be effective in reducing the incidence and / or severity of opioid-induced cough. 1,3–9 However, there are potential risks associated with these pharmacological interventions and it is therefore necessary to identify an alternative pretreatment agent with minimal complications to reduce sufentanil-induced cough. Alfentanil is a synthetic, short-acting opioid analgesic classified as a small molecule derivative of fentanyl. Alfentanil exhibits the less potency, the faster onset and shorter duration of action compared to analogous anesthetics such as fentanyl and sufentanil, making it an ideal analgesic supplement during various surgical procedures. In addition, alfentanil injection could prevent bronchial spasms and reduce airway secretions, 10 and its single bolus administration has been reported to be useful in reducing cough during emergence -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal